This site is intended for healthcare professionals

MHRA approves Lumykras for patients with previously treated metastatic NSCLC with KRAS G12C mutation and early access is granted to the NHS.-Amgen

Read time: 1 mins
Last updated:11th Sep 2021
Published:11th Sep 2021
The UK MHRA has approved Lumykras (sotorasib) for patients with previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC) with the KRAS G12C mutation, and according to Amgen, patients in England, Wales and Scotland will be the first in Europe to receive the drug. The European Commission has not yet approved Lumykrag, so patients in Northern Ireland – which remains under the EU regulatory framework – will have to wait for access for a while.
Condition: NSCLC/KRAS G12C
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest